Thursday, April 28, 2016
The Weill Family Foundation and Joan and Sanford I. “Sandy” Weill have donated $185 million to establish the University of California San Francisco Weill Institute for Neurosciences, in an effort to accelerate the development of new therapies for diseases affecting the brain and nervous system, including psychiatric disorders.
Scientists are teaching computers to figure out why people accept or decline invitations to participate in clinical trials. Recruiting sufficient numbers of participants is a current challenge in medical research that can compromise results or stop some studies altogether.
PRA Health Sciences has been recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.
Viveve Medical, a company focused on women’s health, has announced positive top-line results from the VIVEVE I clinical study. The VIveve Treatment of the Vaginal Introitus to EValuate Efficacy study is the first randomized, single-blinded and sham-controlled trial designed to demonstrate the efficacy and safety of the Viveve Treatment versus a sham control procedure for the treatment of vaginal introital laxity.
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators. This is just one of the tools generated through the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort launched by the National MS Society and Critical Path Institute (C-Path). MSOAC is striving to develop an outcomes measure that addresses the critical need for a more sensitive way to detect the benefit of potential treatments that slow or reverse progressive disability in people with MS.
Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.
Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.